Esperion Therapeutics, Inc. (0IIM.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 775.34M |
| Enterprise Value | 1.16B |
| P/E Ratio | -131.4 |
| PEG Ratio | -0.4 |
| Price/Sales Ratio | 1.58 |
| Price/Book Ratio | -2.6 |
| Enterprise/Revenue | 2.51 |
| Enterprise/EBITDA | 26.29 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | -0.02 |
| Operating Margin | 0.18 |
AD
Management Effectiveness
| Return On Assets | -0.02 |
| Return On Equity | 0.02 |
Income Statement
| Revenue | 403.14M |
| Revenue/Share | 1.66 |
| Gross Profit | 273.91M |
| EBITDA | 60.38M |
| Net Income | -22.68M |
| Diluted EPS | -0.11 |
Balance Sheet
| Total Cash | 156.16M |
| Total Cash/Share | 0.62 |
| Total Debt | 543.81M |
| Total Debt/Equity | -1.77 |
| Current Ratio | 1.53 |
| Book Value Per Share | -1.23 |
Price History
| 52-Week Change | 163.6 |
| 52-Week High | 3.32 |
| 52-Week Low | 0.71 |
| Moving Average 50 Days | 2.51 |
| Moving Average 200 Days | 1.67 |
Statistics
| Average Volume | 26,659 |
| Shares Outstanding | 221.64M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
